Cardiff Oncology (CRDF) said late Monday that a phase 1b trial of onvansertib in combination with paclitaxel to treat metastatic triple-negative breast cancer demonstrated a 40% objective response rate at a dosage of 18 milligrams per square meter, with two confirmed and two unconfirmed partial responses.
The trial evaluated three doses of the drug combination, and objective responses were observed at the highest dose of onvansertib, the company said.
The drug combination was well-tolerated and recorded a safe and manageable toxicity profile. Myelosuppression was the most common adverse event, the company added.
Cardiff presented the data at the American Society of Clinical Oncology Annual Meeting in Chicago.
Shares of the company were up 2.7% in after-hours activity.
Price: 3.44, Change: +0.09, Percent Change: +2.69
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.